JMP Securities Reiterates Market Outperform on Acrivon Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating for Acrivon Therapeutics (NASDAQ:ACRV) and maintained a price target of $17.
September 16, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Acrivon Therapeutics, maintaining a $17 price target. This suggests confidence in Acrivon's potential for growth.
The reiteration of a Market Outperform rating and a maintained price target of $17 by JMP Securities indicates a positive outlook on Acrivon Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100